Come and join us on 6 July and hear 4 AIM CEO’s speak. Brad George, Orosur CEO updates us on Colombia’s Tier-1 gold mine potential, Cliff Gross, CEO at Tekcapital explains how investors benefit from a special dividend. Please register here.
Totally agree Ear, think the Singapore thingy could be a very nice curveball if it’s verified, also believe a fourth Facility is not very far off, so many rolls of the dice to come, the DIM is the biggie for me. GLA.
Well stated ear, nothing to wet your pants about, just another day on Aim, topped up again today, long term this is a no brainer, show me another better stock on Aim. As Maximus Decimus Meridius shouted hold the line, hold the line. GLA.
RE: Short term dip & LTH buying opportunity21 Apr 2021 20:33
No bs bar, I sold my other stocks and put it all in Orph, at the IPO of 6p been buying small amounts now and again on the way up, this is the only stock I hold, I know it goes against logic, but I have been investing for over 20 yrs, so for me this is the last throw of the dice. First time I saw CF presenting he made a massive impression, I have not been disappointed so far,hell of a lot more to come. GLA.
RE: Short term dip & LTH buying opportunity21 Apr 2021 13:12
My average is 8p been in since 6p, still brought more last week at 41p, nothing wrong with buying on increasing share price when a Company like Orph has so many irons in the fire, and has so far to go, mind boggling what this Company’s value will eventually be. GLA.
Well stated Moni, I remember when his missis was crying her eye’s out because her dear little boy had to leave the Family nest to go to University, when her hubby had sent score’s of young men to b slaughtered in Iraq, makes my blood boil. Rant over.
Terence Stephenson, Chair of the HRA, said: “There’s very little research that carries zero risk. A challenge trial application would have to make the argument that the benefits to society greatly outweighs the risk and that evidence or data could not be achieved in a simpler or safer way.” Seems a no brainer to me.
RE: 7 china companies mentioned??11 Feb 2021 22:47
While regulatory policy is well defined for orphan drug development in the United States and Europe, rare disease policy in China is still evolving. Many Chinese patients currently pay out of pocket for international treatments that are not yet approved in China. The lack of a clear definition and therefore regulatory approval process for rare diseases has, until now, de-incentivized pharmaceutical companies to pursue rare disease drug development in China. In turn, many grassroots movements have begun to support rare disease patients and facilitate drug discovery through research. Recently, the Chinese FDA set new regulatory guidelines for drugs being developed in China, including an expedited review process for life-saving treatments. Now I wonder who could help the Chinese with this predicament.
RE: 7 china companies mentioned??11 Feb 2021 21:54
There was talk previously of going with the Chinese for the development of The human challenge study but the decision was made to keep it in house, therefore total control, remember CF confirming this in one of his previous interviews. GLA.